The leading Chinese dietary supplement provider, By-Health, has launched a digestive health product called Hericum Erinaceus & Lactobacillus Reuteri based on Organobalance’s proprietary ingredient Pylopass.
This newly launched product uses Pylopass as a core ingredient in order to meet the health needs of Chinese customers.
About 60-80% of the population in China is infected with Helicobacter pylori. Pylopass is highly specific in its action of binding and removing the carcinogenic stomach bacteria, lowering the H. pylori load while keeping the natural gut microbiota balance intact.
New studies have shown that Pylopass also helps in improving the symptoms associated with gastritis and increases the efficacy of the pharmaceutical treatment.
Over the years, resistance has been developed against the conventional antibiotics used for the treatment of H. pylori thereby lowering the success rates of antibiotic therapies significantly.
Pylopass is currently marketed in most European, American and Asian markets where customers rely heavily on this product for gastric well-being.
By-Health will be using Pylopass in its product portfolio and thereby provide the Chinese people access to an effective and natural way of controlling the stomach bacterium.